Prevention of Hepatitis C Virus (HCV) and HIV-1 Co-Infections
A collaborative project financed by the EC Framework Programme 7
ReiThera is a clinical-stage biopharmaceutical company developing genetic vaccines for major infectious diseases, including malaria, HCV and influenza, using a novel proprietary technology.
ReiThera has developed a technology platform centered on the development of new, potent, replication-incompetent Adenovirus vectors, derived from strains isolated from chimpanzees (ChAd) and used to encode and deliver prophylactic and therapeutic antigens. These vectors are not neutralized by human sera, and generate effective T cell responses.
This ground-breaking approach overcomes the major limitation of first-generation vectors, opening the door to the development of important new vaccines in the field of infectious diseases and cancer.